What the Study Found
Scientists tested a special form of vitamin B12 called NO‑Cbl. The goal was to see if it could reach brain tumors and help current medicines work better.
Why Glioblastoma Is Hard to Treat
Glioblastoma is a fast‑growing brain cancer. Even with surgery, radiation, and chemotherapy, most patients live less than 15 months after diagnosis. One big problem is the blood‑brain barrier, a protective wall that blocks many medicines from reaching the tumor.
Testing the B12‑Based Drug
The team tried NO‑Cbl in several ways. They looked at how it affected cancer cells in a laboratory panel, measured how the drug moved through the bodies of rats with brain tumors, and mixed it with other medicines in human glioblastoma cells.
Across many cancer types, NO‑Cbl slowed down cell growth. Brain‑derived tumor cells showed a moderate response, suggesting the drug can act on these cells.
Crossing the Blood‑Brain Barrier
When the drug was given to rats, it traveled through the bloodstream, crossed the protective barrier, and gathered mostly in the tumor area. The researchers found that nitrate levels—an indicator of the drug’s activity—stayed high in tumor tissue for at least a day, while they dropped quickly in normal brain tissue. This means the drug may stay inside the tumor longer, delivering nitric oxide where it is needed.
Working Better With Existing Treatments
In lab experiments with two glioblastoma cell lines (U87 and D54), the scientists combined NO‑Cbl with either TRAIL or temozolomide, two drugs already used against this cancer. The combination killed many more tumor cells than any single drug alone. The results showed a clear synergy, meaning the drugs helped each other work stronger.
How the Drug Might Overcome Resistance
Earlier studies suggest NO‑Cbl can trigger cell death pathways, block survival signals, and boost TRAIL‑related killing. These actions could make tumors that no longer respond to temozolomide become sensitive again.
What Comes Next
Future work will test the compound in more realistic brain‑tumor models, fine‑tune the dose, watch nitric‑oxide effects for longer periods, and explore how the drug works in other brain cancers.
Overall, the early data point to a vitamin B12‑based nitric‑oxide donor as a promising new tool for fighting glioblastoma. By getting past the blood‑brain barrier, focusing on tumor tissue, and boosting existing therapies, NO‑Cbl could help doctors treat one of the toughest brain cancers more effectively.